tbuckley/cabot-search huggingface dataset:
Multicentric observational study to assess clinical characteristics of HER2-positive breast cancer patients treated with adjuvant anti-HER2 therapy.
Authors: M. Seguí, J. Llararmendi, J. Florián Gericó, M. García Lopez, B. Esteban, J. Puertas Alvarez, E. Adrover, S. Ayuga, J. Batista, I. Blancas
Journal: Journal of Clinical Oncology (2010)

e11093 Background: The standard treatment for HER2-positive breast cancer patients is trastuzumab, which improves disease-free survival when used in the adjuvant setting, in combination or following chemotherapy. Our purpose was to assess clinical characteristics of HER2-positive primary breast cancer (PBC) patients treated with anti-HER2 therapy. Methods: A multicentric, observational, transversal study was performed. All patients with HER2-positive PBC treated with adjuvant anti-HER2 therapy were eligible. Results: A total of 230 women treated with adjuvant trastuzumab were evaluated. Median age: 53.2 years (45-78); PS 0: 200 (87%), PS 1: 28 (12.2%); Postmenopausic: 121 (52.6%). Stage IIA: 68 (30%). Infiltrating ductal carcinoma: 209 (91%). Tumor histologic grade III was present in 54%. Overexpression of HER2 was assessed by immunohistochemistry in 99.6% of patients, of whom 88.3% were HER2-postive (3+). Positive Progesterone receptors (PR): 105 (46.3%); Positive Estrogen receptors (ER): 122 (53.7%); PR (+)/ER (+): 91 (40.1%). Fifty percent underwent radical mastectomy. 64% had positive axillary nodes and 36% were node-negative. 24% received neoadjuvant chemoteraphy and 74% adjuvant chemotherapy. Adjuvant radiotherapy: 173 (75.2%); adjuvant hormonal therapy: 140 (60.9%). Antracicline and taxanes based combination was the most frequent chemotherapy in the neo-adjuvant (77%) and adjuvant setting (65%), especially in node-positive patients. Platinum-based chemotherapy was only used in 10% and 5% of patients with neoadjuvant and adjuvant therapy respectively. Trastuzumab was administered following chemotherapy in 65.4%, showing a higher percentage of node-negative patients (75%) than those node-positive (60%) (p < 0.05). Adjuvant trastuzumab was administered every 3 weeks in 87% whereas 13% received a weekly administration, without significant differences between node-positive or negative patients. Conclusions: The characterization of HER2-positive PBC patients that receive adjuvant trastuzumab and their treatment patterns may guide oncologists about patient's eligibility for trastuzumab-based adjuvant therapy. No significant financial relationships to disclose.
Identification of Lipidomic Signatures That Define Three Specific Subtypes of Nafld and Differentiate Nash from Simple Steatosis
Authors: C. Alonso, D. Fernández-Ramos, M. Iruarrizaga-Lejarreta, M. Varela, I Martínez-Arranz, M. Noureddin, M.L. Martínez-Chantar, S.C. Lu, P. Ortiz, J.M. Mato
Journal: Journal of Hepatology (2016)
From Mice to Men – Changes in FGF15/19 Expression and Bile Acid Levels as Sensitive Markers of Pharmacological FXR Activation; Results from Human Phase I and Animal Studies Using the Potent and Selective FXR Agonist Px-102
Authors: E. Hambruch, H. Krol, S. Perović-Ottstadt, M. Hornberger, C. Steeneck, O. Kinzel, U. Deuschle, M. Birkel, C. Kremoser
Journal: Journal of Hepatology (2016)
Liver Transplantation for Children with Acute Liver Failure Associated with Secondary Haemophagocytic Lymphohistiocytosis
Authors: A. Amir, S. Ling, A. Naqvi, S. Weitzman, A. Fecteau, D. Grant, A. Ghanekar, M. Cattral, N. Nalli, B. Kamath, N. Jones, M. DeAngelis, V. Ng, Y. Avitzur
Journal: Journal of Hepatology (2016)
Tumor response assessment by Choi criteria in localized high-risk soft tissue sarcoma (STS) treated with chemotherapy (CT): Update at 10-year follow-up of an exploratory analysis on a phase III trial.
Authors: Silvia Stacchiotti, Paolo Verderio, Antonella Messina, Carlo Morosi, Paola Collini, Antonio Llombart-Bosch, Javier Martin Broto, Alessandro Comandone, Josefina Cruz, Stefano Ferrari, Giovanni Grignani, Stefano Bottelli, Vittorio Quagliuolo, Piero Picci, Antonino De Paoli, Angelo Paolo Dei Tos, Paolo Giovanni Casali, Alessandro Gronchi
Journal: Journal of Clinical Oncology (2016)

11044 Background: We already reported (Cancer 2012;118:5857) on better correlation of Choi criteria (Choi) than RECIST with the outcome of pts affected by high-risk STS entering a multicentric Italian/Spanish Phase 3 trial comparing 3 vs 5 cycles of (neo)adjuvant CT with full-dose epirubicin + ifosfamide (JCO 2012;30:850). We herein update these results with a longer FU. Methods: All pts were treated by 3 cycles of preop Epirubicin + Ifosfamide +/- RT. The diagnostic concordance between RECIST and Choi and their association with overall survival (OS) and freedom from progression (FFP) were assessed by a univariate Cox regression model. The prognostic value of histology was also investigated. Results: At a 115-mo (IQ range 102-129) median FU, in 243 evaluable pts (of 321 eligible pts), univariate Cox regression analysis confirmed the prognostic role of RECIST and Choi, and histology for both OS and/or FFP. Pts with leiomyosarcoma had the lowest PR rate, both those receiving preoperative CT alone and those receiving CT+RT. By contrast, undifferentiated pleomorphic sarcoma (UPS) had the highest response rate (whether receiving CT or CT+RT). Leiomyosarcoma and UPS were associated with the worst and best prognosis, respectively. Finally, in the subgroup of 69 pts treated with CT alone and evaluable by both Choi and RECIST criteria, Choi response was associated with a better OS (PD vs PR: HR = 5.27, 95%CI = 2.02-13.72; SD vs PR: HR = 2.40, 95%CI = 0.93-6.21), while RECIST did not (PD vs PR: HR = 2.21, 95%CI = 0.76-6.38; SD vs PR: HR = 0.56, 95%CI = 0.23-1.36). Conclusions: In this (neo)adjuvant trial, tumor response to CT + RT predicted a better outcome. Choi criteria were a better predictor than RECIST. Leiomyosarcoma fares worse than other histotypes. In an ongoing prospective trial in localized high-risk limb and trunk wall STS, perfusion/diffusion MR and PET are explored to assess tumor response, in addition to RECIST and Choi. Clinical trial information: 2004-003979-36.
Expansion of tumor-infiltrating lymphocytes (TIL) from human pancreatic tumors
Authors: MacLean Hall, Hao Liu, Mokenge Malafa, Barbara Centeno, Pamela J. Hodul, José Pimiento, Shari Pilon-Thomas, Amod A. Sarnaik
Journal: Journal for ImmunoTherapy of Cancer (2016)

<h3>Background</h3> We evaluated whether tumor infiltrating lymphocytes (TIL) could be expanded from surgically resected tumors from pancreatic cancer patients. <h3>Methods</h3> Tumors were resected from pancreatic cancer patients. Tumors were minced into fragments and cultured in media containing high dose interleukin-2 (IL-2) for up to 6&nbsp;weeks. T cell phenotype, activation markers, and reactivity were measured. <h3>Results</h3> TIL expansion was measured in 19 patient samples. The majority of these TIL were CD4<sup>+</sup> T cells and were highly activated. Purified CD8<sup>+</sup> T cells produced IFN-γ in response to HLA-matched pancreatic tumor targets. PD-1 blockade and 4-1BB stimulation were demonstrated as effective strategies to improve effective TIL yield, including the production of tumor-reactive pancreatic TIL. <h3>Conclusions</h3> TIL expanded from pancreatic tumors are functional and able to respond to pancreatic tumor associated antigens. PD-1 blockade, 41BB stimulation, and CD8<sup>+</sup> T cell enrichment are effective strategies to improve TIL yield and tumor reactivity. These results support the development of adoptive cell therapy strategies using TIL for the treatment of pancreatic cancer.
High Efficacy of Interferon-Free Treatments in Real-World Patients with Chronic Hepatitis C a Multicentric Study
Authors: H. Ramos, E. Badia, P. Linares, I. Martín, C. Almohalla, F. Jorquera, I. García, M. Vásquez, P. Conde, B. Alvarez, G. Karpman, J. Gómez, S. Lorenzo, V. Gozalo, D. Joao, M. de Benito, L. Ruiz, F. Jiménez, F. Sáez-Royuela
Journal: Journal of Hepatology (2016)
Sildenafil Reduces Neuroinflammation and Restores Spatial Learning in Rats with Hepatic Encephalopathy. Underlying Mechanisms
Authors: V. Hernandez-Rabaza, A. Agusti, A. Cabrera-Pastor, L. Taoro-Gonzalez, C. Montoliu, M. Llansola, V. Felipo
Journal: Journal of Hepatology (2016)
Antiviral Therapy for the Prevention of Long-Term Cirrhosis Risk in Patients with Chronic Hepatitis B
Authors: H.-I. Yang, J. Hoang, D. Lin, J. Liu, H.-H. Hu, M.-H. Lee, N.H. Nguyen, Y. Kim, C.-L. Jen, V. Vu, A. Le, K. Chaung, V. Nguyen, H. Trinh, J. Li, J. Zhang, A. Hsing, C.-J. Chen, M.H. Nguyen
Journal: Journal of Hepatology (2016)
Regulation of P53 Family Gene Expresion and AKT/JNK Cell Signaling Pathways by Sorafenib in Hepatocarcinoma Cell Lines
Authors: M.A. Rodríguez-Hernández, E. Navarro-Villarán, S. Pereira, L. Barrera-Pulido, A. Gila-Bohórquez, Á. Nogales-Muñoz, D. Pacheco, M.A. Torres-Nieto, A. Serrablo-Requejo, G. Blanco-Fernández, J.M. Álamo-Martínez, C. Bernal-Bellido, J. Serrano-Díaz-Canedo, G. Suárez-Artacho, L.M. Marín-Gómez, T. Ferrer-Ríos, J.M. Pascasio-Acevedo, M.A. Gómez-Bravo, J. Padillo, J. Muntané
Journal: Journal of Hepatology (2016)
Magnetic Resonance Imaging More Accurately Classifies Steatosis and Liver Fibrosis in Non-Alcoholic Fatty Liver Disease than Transient Elastography
Authors: K. Imajo, Y. Honda, T. Kessoku, W. Tomeno, Y. Ogawa, H. Mawatari, K. Fujita, M. Yoneda, S. Saito, A. Nakajima
Journal: Journal of Hepatology (2016)
Liver Transplantation for Chronic HCV Infection in the United States 2002-2014: An Analysis of the UNOS/OPTN Database
Authors: G. Dultz, B. Graubard, P. Martin, M.W. Welker, B. Borg, S. Zeuzem, K.A. McGlynn, T.M. Welzel
Journal: Journal of Hepatology (2016)
Tipping the Balance Toward Fewer Antibiotics
Authors: Ateev Mehrotra, Jeffrey A. Linder
Journal: JAMA Internal Medicine (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Expression of the ETS Transcription Factor GABPα Is Correlated to BCR-ABL/ABL ratio in Human CML and Mediates Imatinib Sensitivity
Authors: Georgi Manukjan, Tim Ripperger, Laura Santer, Nils von Neuhoff, Arnold Ganser, Axel Schambach, Brigitte Schlegelberger, Doris Steinemann
Journal: Blood (2014)
The Association between Pnpla3 Polymorphisms and Fibrosis Progression and Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis C
Authors: N. Tamaki, M. Kurosaki, M. Higuchi, H. Takada, N. Nakakuki, Y. Yasui, S. Suzuki, H. Nakanishi, J. Itakura, N. Izumi
Journal: Journal of Hepatology (2016)
Impact Of a Federal Program On response Rate &amp; Survival, In a Cohort Of Patients With Diffuse Large B- Cell Lymphoma. Analysis In a Single National Reference Institution In Mexico
Authors: Myrna Candelaria, Juan Labardini, Ana Florencia Ramirez, Alejandro Aviles, Enrique Estrada-Lobato, Abelardo Meneses-Garcia, Md, Alejandro Mohar
Journal: Blood (2013)
Real World Evaluation of Viekira Pak (Ritonavir Boosted Paritaprevir, Ombitasvir and Dasabuvir +/− Ribavirin) in HCV Genotype 1 Targeting Advanced Liver Disease (The Revital Study)
Authors: J.S. Lubel, S. Pianko, A. Thompson, S. Strasser, K. Stuart, P. Gow, J. Mitchell, A. Gazzola, S. Chivers, G. Mishra, S. Nazareth, T. Jones, J. Gough, S. Bollipo, A. Wade, E. Tse, G. MacQuillan, J. George, S. Roberts
Journal: Journal of Hepatology (2016)
Targeting Immune Checkpoints in Hematologic Malignancies
Authors: Gheath Alatrash, Naval Daver, Elizabeth A. Mittendorf
Journal: Pharmacological Reviews (2016)

The use of antibodies that target immune checkpoint molecules on the surface of T-lymphocytes and/or tumor cells has revolutionized our approach to cancer therapy. Cytotoxic-T-lymphocyte antigen (CTLA-4) and programmed cell death protein 1 (PD-1) are the two most commonly targeted immune checkpoint molecules. Although the role of antibodies that target CTLA-4 and PD-1 has been established in solid tumor malignancies and Food and Drug Administration approved for melanoma and non-small cell lung cancer, there remains a desperate need to incorporate immune checkpoint inhibition in hematologic malignancies. Unlike solid tumors, a number of considerations must be addressed to appropriately employ immune checkpoint inhibition in hematologic malignancies. For example, hematologic malignancies frequently obliterate the bone marrow and lymph nodes, which are critical immune organs that must be restored for appropriate response to immune checkpoint inhibition. On the other hand, hematologic malignancies are the quintessential immune responsive tumor type, as proven by the success of allogeneic stem cell transplantation (allo-SCT) in hematologic malignancies. Also, sharing an immune cell lineage, malignant hematologic cells often express immune checkpoint molecules that are absent in solid tumor cells, thereby offering direct targets for immune checkpoint inhibition. A number of clinical trials have demonstrated the potential for immune checkpoint inhibition in hematologic malignancies before and after allo-SCT. The ongoing clinical studies and complimentary immune correlatives are providing a growing body of knowledge regarding the role of immune checkpoint inhibition in hematologic malignancies, which will likely become part of the standard of care for hematologic malignancies.
Investment in general practice rises slightly after years of cuts
Authors: Adrian O’Dowd
Journal: BMJ (2016)

The amount of money invested into general practice in the United Kingdom has fallen by around 2% over the past decade but has slightly improved in the past few years, new figures have shown.

A report published on 21 September by NHS Digital showed a slight upturn after years of falling investment.1

The government allocated £11.03bn (€12.84bn; $14.32) to general practice in the UK in 2015-16, which represented a 4.36% increase on the previous year (£10.57bn). Excluding drugs reimbursement, UK funding rose by 4.67% (£10.31bn in 2015-16 compared with £9.85bn in 2014-15).

However, the BMA has called on …
Influence of Donor and Recipient Gender on Liver Transplantation Outcomes in Europe: A Eltr Study
Authors: G. Germani, A. Ferrarese, R. Adam, V. Karam, L. Belli, J. O’Grady, D. Mirza, J. Klempnauer, D. Cherqui, J. Pratschke, N. Jamieson, M. Salizzoni, H. Hidalgo, J. Lerut, A. Paul, J.C. Garcia-Valdecasas, F.S.J. Rodriguez, P. Burra
Journal: Journal of Hepatology (2016)
PD1.02 (also presented as P2.47): The Role of PD-L1 Expression as a Predictive Biomarker in Advanced NSCLC: An Update of a Network Meta-Analysis
Authors: Pedro Aguiar, Gilberto Lopes, Ilka Santoro, Hakaru Tadokoro, Carmelia Barreto, Ramon De Mello
Journal: Journal of Thoracic Oncology (2016)
Disease-Related Variants in Genes Involved in Bile Formation and Transport Demonstrated in 12 of 22 Patients with “Unexplained Cholestasis” by the Use of a Novel Panel for Genetic Testing
Authors: L. Aamann, N. Ørntoft, D. Lildballe, H. Grønbæk, H. Vilstrup, I. Vogel, P. Ott
Journal: Journal of Hepatology (2016)
NT1014, a novel biguanide, inhibits ovarian cancer growth in vitro and in vivo
Authors: Lu Zhang, Jianjun Han, Amanda L. Jackson, Leslie N. Clark, Joshua Kilgore, Hui Guo, Nick Livingston, Kenneth Batchelor, Yajie Yin, Timothy P. Gilliam, Paola A. Gehrig, Xiugui Sheng, Chunxiao Zhou, Victoria L. Bae-Jump
Journal: Journal of Hematology & Oncology (2016)

NT1014 is a novel biguanide and AMPK activator with a high affinity for the organic cation-specific transporters, OCT1 and OCT3. We sought to determine the anti-tumorigenic effects of NT1014 in human ovarian cancer cell lines as well as in a genetically engineered mouse model of high-grade serous ovarian cancer.The effects of NT1014 and metformin on cell proliferation were assessed by MTT assay using the human ovarian cancer cell lines, SKOV3 and IGROV1, as well as in primary cultures. In addition, the impact of NT1014 on cell cycle progression, apoptosis, cellular stress, adhesion, invasion, glycolysis, and AMPK activation/mTOR pathway inhibition was also explored. The effects of NT1014 treatment in vivo was evaluated using the K18 - gT121+/-; p53fl/fl; Brca1fl/fl (KpB) mouse model of high-grade serous ovarian cancer.NT1014 significantly inhibited cell proliferation in both ovarian cancer cell lines as well as in primary cultures. In addition, NT1014 activated AMPK, inhibited downstream targets of the mTOR pathway, induced G1 cell cycle arrest/apoptosis/cellular stress, altered glycolysis, and reduced invasion/adhesion. Similar to its anti-tumorigenic effects in vitro, NT1014 decreased ovarian cancer growth in the KpB mouse model of ovarian cancer. NT1014 appeared to be more potent than metformin in both our in vitro and in vivo studies.NT1014 inhibited ovarian cancer cell growth in vitro and in vivo, with greater efficacy than the traditional biguanide, metformin. These results support further development of NT1014 as a useful therapeutic approach for the treatment of ovarian cancer.
Translational Aspects of the Human Respiratory Virome
Authors: Alicia B. Mitchell, Brian G. G. Oliver, Allan R. Glanville
Journal: American Journal of Respiratory and Critical Care Medicine (2016)

Section:ChooseTop of pageAbstract <<The Human MicrobiomeThe Human ViromeThe Human Respiratory Vir...LimitationsConclusionsReferencesCITING ARTICLES
RTRB-09SALVAGE STEREOTACTIC RADIOSURGERY TO RECURRENT GLIOBLASTOMA MULTIFORME FOLLOWING PRIOR RADIOTHERAPY
Authors: Douglas Holt, Mark Bernard, Kimmen Quan, David Clump, Johnathan Engh, Steven Burton, Dwight Heron
Journal: Neuro-Oncology (2015)

BACKGROUND: Due to the poor prognosis of glioblastoma multiforme (GBM) and high recurrence rates, salvage stereotactic radiosurgery (SRS) may be an effective treatment option given its ability to deliver a high dose of radiation within a small volume. Here we investigate the efficacy of salvage SRS for recurrent GBM. METHODS: We retrospectively reviewed 34 patients (41 lesions) treated with salvage SRS for recurrent GBM between 2004-2012. Initial surgical treatments were as follows: gross total resection (58%), subtotal resection (24%), and biopsy (18%). All patients were treated with prior radiotherapy. Recurrent disease was treated with salvage SRS with a median dose of 23.4 Gy (range 12-30) and delivered in a median fraction number of 3 (range 1-3). Cox proportional hazards regression was conducted to establish prognostic factors (p < 0.05). RESULTS: Median follow-up from salvage SRS was 10.8 months (IQR 7.0-15.6). The median time from initial radiotherapy to salvage SRS was 13.7 months (IQR 2.9-25.0). The 6- and 12-month overall survival from salvage SRS were 84.9% and 42.5%, respectively. Upon univariate analysis, subtotal resection (HR = 2.8, p = 0.021) was associated with inferior survival from salvage SRS. The 6- and 12-month local control estimates were 63.1%, and 16.4%, respectively. Using univariate analysis, higher BED (HR = 0.99, p = 0.018) was associated with superior local control. Neither time to recurrence or recurrent tumor volume were associated with local failure. Concerning toxicity, there were 4 (12%) grade 2 and 1 (3%) grade 3 radiation-related toxicities. No grade 4 or 5 toxicities were observed. CONCLUSIONS: Salvage radiosurgery provides an intriguing treatment option for recurrent GBM with minimal toxicity. Our outcomes suggest this is a feasible treatment option with acceptable salvage survival rates given the poor prognosis this diagnosis carries.
Allelically Mismatched Replacement Therapy Due to Common African−Restricted Haplotypes of the Factor (F)VIII Protein May Underlie the Increased Incidence of FVIII Inhibitors Observed in Hemophilia−A Patients of African−Descent.
Authors: Tom E. Howard, Kevin R. Viel, Karl M. Fernstrom, Seema Deshpande, Afshin Ameri, M. Showkat Ali, Cynthia Channell, Rathi V. Iyer, Raymond G. Watts, Charles Lutcher, Shelley Nakaya, Carol K. Kasper, Arthur R. Thompson, Thomas C. Abshire, Laura Almasy
Journal: Blood (2006)
Melatonin Impairs the Inflammatory Response and Inhibits the Sphingosine Kinase Signaling Pathway in an Animal Model of Liver Fibrosis
Authors: B. González-Fernández, D.I. Sanchéz, B. San-Miguel, I. Crespo, J.O. de Urbina, M. Álvarez, J. González-Gallego, M.J. Tuñón
Journal: Journal of Hepatology (2016)
A Phase I Study of CHR-2797, an Orally Active Aminopeptidase Inhibitor in Elderly and/or Treatment Refractory Patients with Acute Myeloid Leukemia or Multiple Myeloma.
Authors: Faith Davies, Gert Ossenkoppele, Pierre Zachee, Richard Noppeney, Alan Burnett, Michel Delforge, Pieter Sonneveld, Gareth Morgan, Sonja Zweegman, Dimitri Breems, Alison Richardson, Leon Hooftman, Bob Lowenberg
Journal: Blood (2007)
Toward a Shared Vision for Cancer Genomic Data
Authors: Robert L. Grossman, Allison P. Heath, Vincent Ferretti, Harold E. Varmus, Douglas R. Lowy, Warren A. Kibbe, Louis M. Staudt
Journal: New England Journal of Medicine (2016)

The Genomic Data Commons will initially house raw genomic data and diagnostic, histologic, and clinical outcome data from National Cancer Institute–funded projects. A harmonization process will align sequencing data to the genome and identify mutations and alterations.
Determination of Ledipasvir Concentrations in Patients with Decompensated Cirrhosis Receiving Low Dose Proton Pump Inhibitors during Sofosbuvir-Ledipasvir Treatment for HCV Genotype 1 Infection
Authors: O. El-Sherif, S. Stewart, C. Bergin, S. McKiernan, O. Crosbie, S. Khoo, S. Norris
Journal: Journal of Hepatology (2016)
Extensively Drug Resistant Bacteria as an Independent Predictive Factor of Mortality in Spontaneous Bacterial Peritonitis and Spontaneous Bacteremia
Authors: A. Alexopoulou, L. Vasilieva, D. Agiasotelli, K. Siranidi, S. Pouriki, A. Tsiriga, M. Toutouza, S. Dourakis
Journal: Journal of Hepatology (2016)
Genetic Variability of Aurora B Kinase Coding Region in Patients with Chronic Hepatitis C with and without Cirrhosis
Authors: I. Francisco-Recuero, A.I. Gil, A. Madejón, A. Sánchez-Pacheco, M. Romero, A. García, C. Perales, A. Olveira, P. Castillo, J.C. Erdozain, E. Domingo, J. García-Samaniego
Journal: Journal of Hepatology (2016)
Rupture of T Cell Tolerance to Self Factor VIII in Mild/Moderate Hemophilia A.
Authors: Marc G. Jacquemin, Renaud Lavend’homme, Benhida Abdellah, Kathelijne Peerlinck, Jos Vermylen, Véronique Deneys, Jean-Marie Saint-Remy, Cédric Hermans
Journal: Blood (2004)
Retinoic Acid Is a Negative Regulator In Hematopoietic Development and Definitive Hematopoietic Progenitor Maintenance
Authors: Roger Emanuel Rönn, Carolina Guibentif, Roksana Moraghebi, Patricia Chaves Guerrero, Bradley Garcia, Ewa Sitnicka, Niels-Bjarne Woods
Journal: Blood (2013)
Determination of a Normal value for HOMA-IR and cut-off Value for Non-Alcoholic Fatty Liver Disease
Authors: E.M. Petäjä, Y. Zhou, M. Peltonen, P. Jouslahti, S. Männistö, S. Keinänen-Kiukaanniemi, J. Saltevo, H. Yki-Järvinen
Journal: Journal of Hepatology (2016)
Alternatively Spliced Tissue Factor As a New Therapeutic Target in Pancreatic Cancer
Authors: Dusten Unruh, Xiaoyang Qi, Zhengtao Chu, Robert Sturm, Ryan Keil, Syed A Ahmad, Timofey Sovershaev, Janusz W Rak, Nigel Mackman, Henri H Versteeg, Vladimir Y Bogdanov
Journal: Blood (2014)